Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica de La Rioja (29)

2022

  1. CCL5 Levels Predict Stroke Volume Growth in Acute Ischemic Stroke and Significantly Diminish in Hemorrhagic Stroke Patients

    International journal of molecular sciences, Vol. 23, Núm. 17

2021

  1. Adrenomedullin as a potential biomarker involved in patients with hereditary hemorrhagic telangiectasia

    European Journal of Internal Medicine, Vol. 88, pp. 89-95

  2. Adrenomedullin is a diagnostic and prognostic biomarker for acute intracerebral hemorrhage

    Current Issues in Molecular Biology, Vol. 43, Núm. 1, pp. 324-334

  3. Maraviroc prevents hcc development by suppressing macrophages and the liver progenitor cell response in a murine chronic liver disease model

    Cancers, Vol. 13, Núm. 19

  4. Response to Letter to the Editor from Abobaker and Darrat: "circulating levels of Calcitonin Gene-Related Peptide Are Lower in COVID-19 Patients"

    Journal of the Endocrine Society

2020

  1. Author Correction: Lack of adrenomedullin in mouse endothelial cells results in defective angiogenesis, enhanced vascular permeability, less metastasis, and less brain damage (Scientific Reports, (2016), 6, 1, (33495), 10.1038/srep33495)

    Scientific Reports

  2. Macrocybin, a Natural Mushroom Triglyceride, Reduces Tumor Growth In Vitro and In Vivo through Caveolin-Mediated Interference with the Actin Cytoskeleton

    Molecules (Basel, Switzerland), Vol. 25, Núm. 24

2018

  1. Maraviroc improves hepatic triglyceride content but not inflammation in a murine nonalcoholic fatty liver disease model induced by a chronic exposure to high-fat diet

    Translational Research, Vol. 196, pp. 17-30

2017

  1. Small molecules related to adrenomedullin reduce tumor burden in a mouse model of colitis-associated colon cancer

    Scientific Reports, Vol. 7, Núm. 1

2016

  1. Lack of adrenomedullin in mouse endothelial cells results in defective angiogenesis, enhanced vascular permeability, less metastasis, and more brain damage

    Scientific Reports, Vol. 6

  2. Off-label use of maraviroc in clinical practice

    Expert Review of Anti-Infective Therapy

  3. Temporal profiles of blood pressure, circulating nitric oxide, and adrenomedullin as predictors of clinical outcome in acute ischemic stroke patients

    Molecular Medicine Reports, Vol. 13, Núm. 5, pp. 3724-3734

2015

  1. NEMO Prevents Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1 Kinase Activity-Mediated Hepatocyte Apoptosis

    Cancer Cell, Vol. 28, Núm. 5, pp. 582-598

2014

  1. Adrenomedullin and tumour microenvironment

    Journal of Translational Medicine, Vol. 12, Núm. 1

  2. Death receptor-independent FADD signalling triggers hepatitis and hepatocellular carcinoma in mice with liver parenchymal cell-specific NEMO knockout

    Cell Death and Differentiation, Vol. 21, Núm. 11, pp. 1721-1732

  3. Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 7, pp. 1903-1910

2013

  1. Adrenomedullin Peptides

    Handbook of Biologically Active Peptides (Elsevier Inc.), pp. 990-995

  2. Expression of matrix metalloproteinases and their inhibitors in the woodchuck model of hepatocellular carcinoma

    Journal of Medical Virology, Vol. 85, Núm. 7, pp. 1127-1138

  3. Is the cytoskeleton an intracellular receptor for adrenomedullin and PAMP?

    Current Protein and Peptide Science, Vol. 14, Núm. 5, pp. 429-433

  4. Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model

    PLoS ONE, Vol. 8, Núm. 1